EC Number   |
General Information |
Reference |
|---|
   3.4.24.75 | more |
lysostaphin clears Staphylococcus aureus biofilms in vitro and also eradicates established Staphylococcus aureus biofilms on implanted jugular vein catheters in mice, overview |
708895 |
| 3.4.24.75 | more |
lysostaphin is effective, in combination with antibiotic ranalexin, against methicillin-resistant Staphylococcus aureus infections in human MRSA252 cell culture for hemolysis assay, the female ICR CD-1 mouse model for systemic infection, and a rabbit model for wound infection using New Zealand White rabbits, overview. Ranalexin alone causes hemolysis and shows signs of toxicity to Vero cells at over 50 mg/L, but lysostaphin alone causes no hemolysis and has no effect on Vero cell viability |
708742 |
| 3.4.24.75 | more |
lysostaphin is effective, in combination with antibiotic ranalexin, against methicillin-resistant Staphylococcus aureus infections. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone |
708898 |
| 3.4.24.75 | physiological function |
chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in mouse mammary glands |
718645 |
| 3.4.24.75 | physiological function |
lysostaphin is an anti-staphylococcal enzyme resulting in bacterial lysis and biofilm reduction |
755399 |
| 3.4.24.75 | physiological function |
the enzyme eradicates meticillin-resistant Staphylococcus aureus biofilm |
734460 |
| 3.4.24.75 | physiological function |
the enzyme lyses staphylococcus cell walls by cleaving pentaglycine cross_bridges in their peptidoglycan |
752791 |
